

## 2022 年度 業績

### 論文 (英文)

#### 原著

1. Nakahara S, Ohguri T, Kakinouchi S, Itamura H, Morisaki T, Tani T, Yahara K, Fujimoto N.  
Intensity-Modulated Radiotherapy with Regional Hyperthermia for High-Risk Localized Prostate Carcinoma.  
Cancers 2022 14(2) 400
2. Nagata Y, Matsukawa T, Tomisaki I, Fujimoto N.  
Prognostic Significance of 3-Month Prostate-specific Antigen Level Following Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer.  
Anticancer Research 2022, 42 (2) 1107-1114
3. Kudo Y, Endo S, Tanio M, Saka T, Himura R, Abe N, Takeda M, Yamaguchi E, Yoshino Y, Arai Y, Kashiwagi H, Oyama M, Itoh A, Shiota M, Fujimoto N.  
Antiandrogenic Effects of a Polyphenol in Carex kobomugi through Inhibition of Androgen Synthetic Pathway and Downregulation of Androgen Receptor in Prostate Cancer Cell Lines.  
A. Int J Mol Sci. 2022 Nov 18;23(22):14356
4. Fujimoto N, Minato A, Igawa T, Hiroshige T, Obara W, Fukuda A, Nagata Y, Mizushima Y, Tomisaki I, Harada K.  
Immediate Prostate-specific Antigen Decline After Enzalutamide Following Abiraterone Predicts Survival in Castration-resistant Disease.  
Anticancer Res 2022 Jun;42(6):3041-3047
5. Hamasuna R, Hanzawa H, Moritomo A, Matsumoto M, Aono H, Tomisaki I, Akasaka T, Fujimoto N, Jensen JS.  
Analysis of fluoroquinolone-resistance using MIC determination and homology modelling of ParC of contemporary *Mycoplasma genitalium* strains.  
J Infect Chemother. 2022 Mar;28(3):377-383.

6. Mukai S, Sakamoto N, Kakinoki H, Shibuya T, Moriya R, Nishihara K, Noguchi M, Shin T, Fujimoto N, Igawa T, Ishii T, Haga N, Enokida H, Eto M, Kamba T, Sakai H, Saito S, Terada N, Kamoto T.  
Serum IgG4 Concentration Is a Potential Predictive Biomarker in Glucocorticoid Treatment for Idiopathic Retroperitoneal Fibrosis.  
J. Clin. Med. 2022 11 3538
7. Furubayashi N, Minato A, Negishi T, Sakamoto N, Song Y, Hori Y, Tomoda T, Harada M, Tamura S, Miura A, Komori H, Kuroiwa K, Seki N, Fujimoto N, Nakamura M.  
Association between immune-related adverse events and efficacy and changes in the relative eosinophil count among patients with advanced urothelial carcinoma treated by pembrolizumab.  
Cancer Manag Res. 14: 1641-1651, 2022. doi.10.2147/CMAR.S360473.
8. Kimura H, Mizuno K, Shiota M, Narita S, Terada N, Fujimoto N, Ogura K, Hatano S, Iwasaki Y, Hakozaki N, Ishitoya S, Sumiyoshi T, Goto T, Kobayashi T, Nakagawa H, Kamoto T, Eto M, Habuchi T, Ogawa O, Momozawa Y, Akamatsu S. Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer. Br J Cancer. 2022 Nov;127(9):1680-1690.
9. Kobayashi M, Fujiyama N, Tanegashima T, Narita S, Yamamoto Y, Fujimoto N, Ueda S, Takeuchi A, Numakura K, Habuchi T, Matsuyama H, Eto M, Shiota M. Effect of HLA genotype on intravesical recurrence after bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer.  
Cancer Immunol Immunother. 2022 Mar;71(3):727-736.
10. Shiota M, Fujimoto N, Sekino Y, Tsukahara S, Nagakawa S, Takamatsu D, Abe T, Kinoshita F, Ueda S, Ushijima M, Matsumoto T, Kashiwagi E, Inokuchi J, Uchiumi T, Oda Y, Eto.  
Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer.  
Andrologia. 2022 Feb;54(1):e14307

11. Kudo Y, Endo S, Fujita M, Ota A, Kamatari YO, Tanaka Y, Ishikawa T, Ikeda H, Okada T, Toyooka N, Fujimoto N, Matsunaga T, Ikari A.  
Discovery and Structure-Based Optimization of Novel Atg4B Inhibitors for the Treatment of Castration-Resistant Prostate Cancer.  
J Med Chem. 2022 Mar 24;65(6):4878-4892.
12. Minato A, Noguchi H, Kimuro R, Harada M, Nagata Y, Hasegawa Y, Tomisaki I, Harada K, Fujimoto N.  
Prognostic Value of Squamous Differentiation in Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy.  
Anticancer Res. 2022 Jan;42(1):263-269.
13. Tomisaki I, Harada M, Minato A, Nagata Y, Kimuro R, Higashijima K, Harada K, Fujimoto N.  
Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma.  
Anticancer Res. 2022 Mar;42(3):1629-1634.
14. Suzuki K, Hara T, Terakawa T, Furukawa J, Harada K, Hinata N, Nakano Y, Fujisawa M.  
The Efficacy of Surgical Metastasectomy for Solitary Metastasis of Renal Cell Carcinoma.  
Urol Int. 2022;106(4):397-403.
15. Ueki H, Hinata N, Kitagawa K, Hara T, Terakawa T, Furukawa J, Harada K, Nakano Y, Komatsu M, Fujisawa M, Shirakawa T.  
Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizuma.  
Clin Transl Oncol. 2022 Mar;24(3):568-577.
16. Minato A, Furubayashi N, Harada M, Negishi T, Sakamoto N, Song Y, Hori Y, Tomoda T, Tamura S, Kuroiwa K, Seki N, Tomisaki I, Harada K, Nakamura M, Fujimoto N.  
Efficacy of Pembrolizumab in Patients With Variant Urothelial Carcinoma: A Multicenter Retrospective Study.  
Clin Genitourin Cancer. 2022 Oct;20(5):499.e1-499.e8.

17. Kamijima T, Yaegashi H, Mizokami A, Nakajima K, Matsuyama H, Ichikawa T, Nishimoto K, Takahashi S, Shiina H, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A, Enokida H.  
Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTATE-BSI Sub-analysis  
*Anticancer Res.* 2022 Jun;42(6):3099-3108.
18. Funakoshi Y, Yakushijin K, Ohji G, Hojo W, Sakai H, Takai R, Nose T, Ohata S, Nagatani Y, Koyama T, Kitao A, Nishimura M, Imamura Y, Kiyota N, Harada K, Tanaka Y, Mori Y, Minami H.  
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer.  
*J Infect Chemother.* 2022 Apr;28(4):516-520.
19. Sato R, Inamoto T, Matsushita Y, Takemura A, Uchimoto T, Sano A, Tanaka H, Ishikawa G, Watanabe K, Watanabe H, Tamura K, Motoyama D, Sugiyama T, Otsuka A, Harada K, Azuma H, Miyake H.  
Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab.  
*Int J Urol.* 2022 Dec 27.
20. Yamamoto K, Nishiyama S, Kunisada M, Iida M, Ito T, Ioroi T, Makimoto H, Omura T, Harada K, Fujisawa M, Nishigori C, Yano I.  
Safety and Efficacy of Bis-Glyceryl Ascorbate as Prophylaxis for Hand-Foot Skin Reaction: A Single-Arm, Open-Label Phase I/II Study (DGA Study).  
*Oncologist.* 2022 May 6;27(5):e384-e392.
21. Ueki H, Hara T, Okamura Y, Bando Y, Terakawa T, Furukawa J, Harada K, Nakano Y, Fujisawa M.  
Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: A retrospective study.  
*Investig Clin Urol.* 2022 Jul;63(4):415-424.

22. Ueki H, Terakawa T, Ueno Y, Sofue K, Horii S, Okamura Y, Bando Y, Hara T, Furukawa J, Harada K, Hinata N, Nakano Y, Murakami T, Fujisawa M. Efficacy of preoperative cine magnetic resonance imaging in evaluation of adhesion of renal cancer thrombus to inferior vena cava wall  
J Vasc Surg Venous Lymphat Disord. 2022 Jul;10(4):908-915.
23. Urase Y, Ueno Y, Tamada T, Sofue K, Takahashi S, Hinata N, Harada K, Fujisawa M, Murakami T. Comparison of prostate imaging reporting and data system v2.1 and 2 in transition and peripheral zones: evaluation of interreader agreement and diagnostic performance in detecting clinically significant prostate cancer.  
Br J Radiol. 2022 Mar 1;95(1131):20201434.
24. Ito T, Yamamoto K, Furukawa J, Harada K, Fujisawa M, Omura T, Yano I. Association of sunitinib concentration and clinical outcome in patients with metastatic renal cell carcinoma treated with a 2-week-on and 1-week-off schedule  
J Clin Pharm Ther. 2022 Jan;47(1):81-88.
25. Tomisaki I. Editorial Comment to Tri-modality therapy with i-125 brachytherapy, external beam radiation therapy, and short-term hormone therapy for high-risk prostate cancer after holmium laser enucleation of the prostate.  
IJU Case Rep. 5: 226-227, 2022
26. Furubayashi N, Minato A, Negishi T, Sakamoto N, Song Y, Hori Y, Tomoda T, Harada M, Tamura S, Kobayashi H, Wada Y, Kuroiwa K, Seki N, Fujimoto N, Nakamura M: The eosinophil changes, efficacy and safety of pembrolizumab in advanced urothelial carcinoma patients with an older age and a poor performance status.  
Onco Targets Ther. 15: 1321-1330, 2022. doi.10.2147/OTT.S389138.
27. Matsumoto M, Hamasuna R, Le PT, Fujimoto N, Matsumoto T. Detection of *Neisseria gonorrhoeae* or *Chlamydia trachomatis* from oral wash specimens using the Abbott RealTime CT/NG assay and the Cobas 4800 CT/NG assay: A prospective study.  
J Infect Chemother. 2022 Apr;28(4):480-485.

28. Hamasuna R, Hanzawa H, Moritomo A, Matsumoto M, Aono H, Tomisaki I, Akasaka T, Fujimoto N, Jensen JS.  
Analysis of fluoroquinolone-resistance using MIC determination and homology modelling of ParC of contemporary *Mycoplasma genitalium* strains.  
J Infect Chemother. 2022 Mar;28(3):377-383.
29. Takahashi S, Yasuda M, Wada K, Matsumoto M, Hayami H, Kobayashi K, Miyazaki J, Kiyota H, Matsumoto T, Yotsuyanagi H, Tateda K, Sato J, Hanaki H, Masumori N, Hiyama Y, Egawa S, Yamada H, Matsumoto K, Ishikawa K, Yamamoto S, Togo Y, Tanaka K, Shigemura K, Uehara S, Kitano H, Kiyoshima K, Hamasuna R, Ito K, Hirayama H, Kawai S, Shiono Y, Maruyama T, Ito S, Yoh M, Ito M, Hatano K, Ihara H, Uno S, Monden K, Yokoyama T, Takayama K, Sumii T, Kadena H, Kawahara M, Hosobe T, Izumitani M, Kano M, Nishimura H, Fujita R, Kaji S, Hayashi K, Tojo T, Matumura M.  
Nationwide surveillance of the antimicrobial susceptibility of *Chlamydia trachomatis* from male urethritis in Japan: Comparison with the first surveillance report.  
J Infect Chemother. 2022 Jan;28(1):1-5.
30. Matsukawa T, Doi T, Obayashi K, Sumida K, Fujimoto N, Endo M.  
ANGPTL8 links inflammation and poor differentiation, which are characteristics of malignant renal cell carcinoma.  
Cancer Sci. 2022 Dec 18. doi:10.1111/cas.15700. Online ahead of print.
31. Ichihara K, Takahashi S, Hiyama Y, Masumori N, Nagae H, Ito S, Wada K, Betsunoh H, Hamasuna R, Togo Y, Shigemura K, Takeyama K.  
Distribution of the positive UPOINT domain in patients with chronic prostatitis or chronic pelvic pain syndrome: A multicenter observational study.  
J Infect Chemother. 2022 ;28(5):631-634

## 総説

1. Shiota M, Endo S, Blas L, Fujimoto N, Eto M.  
Steroidogenesis in castration-resistant prostate cancer.  
Urol Oncol. 2022 11:S1078-1439(22)00397

2. Harada K, Shiota M, Minato A, Matsumoto M, Tomisaki I, Fujisawa M, Fujimoto N. Comprehensive assessments of immuno-oncology drug-based combination therapies as first-line treatment for advanced renal cell carcinoma. *Int J Urol*. 2022 May 30. doi: 10.1111/iju.14922. Online ahead of print.